Advertisement

Baseline Plasma Adiponectin Levels as a Predictor of Left Ventricular Systolic Dysfunction in Patients Referred for Coronary Angiography

Published:February 13, 2008DOI:https://doi.org/10.1016/j.amjcard.2007.12.008
      The objective of the present study was to determine the association between plasma adiponectin and left ventricular (LV) systolic function. Baseline plasma adiponectin was measured in 389 patients undergoing coronary angiography for a variety of indications at a Veterans Affairs Medical Center. Detailed demographic, clinical, laboratory, and angiographic data were available for patients. LV systolic function was assessed using ventriculography, and patients were grouped into those with normal or mild dysfunction (ejection fraction ≥45%) versus those with moderate to severe systolic dysfunction (ejection fraction <45%). After adjusting for a variety of clinically relevant covariates known to affect LV systolic function, adiponectin was independently associated with LV systolic function in the entire cohort of patients (p = 0.0002) using multivariate linear regression analysis. In addition, using multivariate logistic regression analysis, adiponectin was an independent predictor of the presence of moderate to severe LV dysfunction (odds ratio 1.54, 95% confidence interval 1.21 to 1.97, p = 0.0005). Moreover, baseline adiponectin was also independently associated with LV function in both the myocardial infarction (MI) and non-MI subpopulations of patients (p = 0.0401 and p= 0.0023, respectively). Finally, in the non-MI subpopulation, baseline adiponectin was an independent predictor of moderate to severe LV systolic dysfunction (odds ratio 1.52, 95% confidence interval 1.15 to 2.02, p = 0.0034). In conclusion, baseline plasma adiponectin was an independent predictor of LV systolic dysfunction in a population of patients referred for coronary angiography.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cavusoglu E.
        • Ruwende C.
        • Chopra V.
        • Yanamadala S.
        • Eng C.
        • Clark L.T.
        • Pinsky D.J.
        • Marmur J.D.
        Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain.
        Eur Heart J. 2006; 27: 2300-2309
        • Menon V.
        • Li L.
        • Wang X.
        • Greene T.
        • Balakrishnan V.
        • Madero M.
        • Pereira A.A.
        • Beck G.J.
        • Kusek J.W.
        • Collins A.J.
        • Levey A.S.
        • Sarnak M.J.
        Adiponectin and mortality in patients with chronic kidney disease.
        J Am Soc Nephrol. 2006; 17: 2599-2606
        • Pilz S.
        • Mangge H.
        • Wellnitz B.
        • Seelhorst U.
        • Winkelmann B.R.
        • Tiran B.
        • Boehm B.O.
        • Marz W.
        Adiponectin and mortality in patients undergoing coronary angiography.
        J Clin Endocrinol Metab. 2006; 91: 4277-4286
        • Kistorp C.
        • Faber J.
        • Galatius S.
        • Gustafsson F.
        • Frystyk J.
        • Flyvbjerg A.
        • Hildebrandt P.
        Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.
        Circulation. 2005; 112: 1756-1762
        • George J.
        • Patal S.
        • Wexler D.
        • Sharabi Y.
        • Peleg E.
        • Kamari Y.
        • Grossman E.
        • Sheps D.
        • Keren G.
        • Roth A.
        Circulating adiponectin concentrations in patients with congestive heart failure.
        Heart. 2006; 92: 1420-1424
        • Kojima S.
        • Funahashi T.
        • Sakamoto T.
        • Miyamoto S.
        • Soejima H.
        • Hokamaki J.
        • Kajiwara I.
        • Sugiyama S.
        • Yoshimura M.
        • Fujimoto K.
        • et al.
        The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction.
        Heart. 2003; 89: 667
        • Shibata R.
        • Sato K.
        • Kumada M.
        • Izumiya Y.
        • Sonoda M.
        • Kihara S.
        • Ouchi N.
        • Walsh K.
        Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment.
        Cardiovasc Res. 2007; 74: 471-479
        • Ouchi N.
        • Shibata R.
        • Walsh K.
        Cardioprotection by adiponectin.
        Trends Cardiovasc Med. 2006; 16: 141-146
        • Liao Y.
        • Takashima S.
        • Maeda N.
        • Ouchi N.
        • Komamura K.
        • Shimomura I.
        • Hori M.
        • Matsuzawa Y.
        • Funahashi T.
        • Kitakaze M.
        Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism.
        Cardiovasc Res. 2005; 67: 705-713
        • Shibata R.
        • Ouchi N.
        • Ito M.
        • Kihara S.
        • Shiojima I.
        • Pimentel D.R.
        • Kumada M.
        • Sato K.
        • Schiekofer S.
        • Ohashi K.
        • et al.
        Adiponectin-mediated modulation of hypertrophic signals in the heart.
        Nat Med. 2004; 10: 1384-1389
        • Shibata R.
        • Izumiya Y.
        • Sato K.
        • Papanicolaou K.
        • Kihara S.
        • Colucci W.S.
        • Sam F.
        • Ouchi N.
        • Walsh K.
        Adiponectin protects against the development of systolic dysfunction following myocardial infarction.
        J Mol Cell Cardiol. 2007; 42: 1065-1074
        • Tsutamoto T.
        • Tanaka T.
        • Sakai H.
        • Ishikawa C.
        • Fujii M.
        • Yamamoto T.
        • Horie M.
        Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure.
        Eur Heart J. 2007; 28: 1723-1730
        • Trujillo M.E.
        • Scherer P.E.
        Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.
        J Intern Med. 2005; 257: 167-175
        • Arita Y.
        • Kihara S.
        • Ouchi N.
        • Takahashi M.
        • Maeda K.
        • Miyagawa J.
        • Hotta K.
        • Shimomura I.
        • Nakamura T.
        • Miyaoka K.
        • et al.
        Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.
        Biochem Biophys Res Commun. 1999; 257: 79-83